Mouton-Liger, F
Rebillat, A-S
Gourmaud, S
Paquet, C
Leguen, A
Dumurgier, J
Bernadelli, P
Taupin, V
Pradier, L
Rooney, T
Hugon, J
Article History
Received: 25 August 2014
Revised: 30 October 2014
Accepted: 3 November 2014
First Online: 15 January 2015
Competing interests
: Professor Jacques Hugon is a consultant for Roche, Sanofi, Novartis, Xigen, Eisai and Lundbeck. Dr. Claire Paquet is a consultant for Lilly and Novartis. Dr. Julien Dumurgier is a consultant for Novartis. Dr. Patrick Bernardelli, Dr. Véronique Taupin, Dr. Thomas Rooney and Dr. Laurent Pradier are fully employed by Sanofi. The remaining authors declare no conflict of interest.